UCB SA is a leading pharmaceutical company based in Belgium that specializes in developing innovative therapies for central nervous system and immunologic diseases. With a low ESG risk rating score of 13.7, UCB is known for its key products including ESG Cimzia, Vimpat, Neupro, Briviact, Bimzelx, Evenity, Nayzilam, and Fintepla. The company has a history of revenue from Zyrtec and Keppra but continues to stay at the forefront of advancements in healthcare.